Companies To Watch: MiroBio

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity

SNAPSHOT

MiroBio is developing checkpoint agonist antibodies aiming to achieve precision targeting of key receptors modulating autoimmune disease. The therapeutics are biological products of rDNA and fermentation, importantly distinguished from the conventional small molecule drugs used currently to treat most autoimmune conditions. The company is betting on the promise of its approach to greatly surpass the conventional drugs in how precisely they target and agonize (i.e., stimulate) the receptors to restore homeostasis. Its lead product, coded MB272, now in late preclinicals, targets the agonist of BTLA (Band T-lymphocyte attenuator) receptor; another, MB151, targets the agonist of PD-1. MiroBio has not disclosed targeted indications for the two lead drugs or released any information on four others in the early pipeline.